Drugs that contain Amifampridine Phosphate
1. List of Firdapse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11274332 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
| US11274331 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
| US11268128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
| US11060128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(9 years from now) | |
| US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(11 years from now) | |
| US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Patient Population (NPP) | Sep 29, 2025 |
NCE-1 date: November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic